reMYND NV today announced that it has received two grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s respectively. VLAIO, the Flemish agency for Innovation and Entrepreneurship, has provided a grant to assess therapeutics for epilepsy.
VIB is organising its 5th Biotechday. All ages are welcome to this free event at campus Gasthuisberg in Leuven. reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide.
reMYND NV today announced that it has received a grant from IWT, the Flemish agency for Innovation by Science and Technology, to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM).
reMYND NV announced today that its experimental diabetes drug ReS39 has demonstrated a strong disease modifying effect in mice, in which the insulin producing capacity of β-cells is preserved - possibly even restored– in a durable way through a novel mechanism of action.
reMYND NV has received a positive ruling from the Belgian Tax Authorities. The ruling stipulates that the upfront license fee, all milestone payments and royalties linked to Roche Basel will qualify for the patent income deduction under Articles 205 WIB 92.
The strategic Alliance between Roche and reMYND to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients is nominated for the Scrip Award “Best Partnership Alliance”. The winners will be announced in London on November 3rd, 2011.
The Science-Business eXchange (SciBX, a publication by the makers of BioCentury and Nature) devoted in its recent publication an article to the role the Michael J Fox Foundation for Parkinson’s Research has been playing in the development of PD therapeutics.
reMYND NV today announced that it has received a grant of 1.48 million EUR from IWT, the Flemish agency for Innovation by Science and Technology, to accelerate its Diabetes program.
In the November 2010 issue of the high impact journal Nature Reviews Drug Discovery, the News&Analysis column has been entirely devoted to the growing interest in targeting protein misfolding to therapeutically treat both rare and common diseases. The column highlights amongst others reMYND’s technology platform and the recently announced Roche-reMYND collaboration for the development of first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease.
Roche (SIX: RO, ROG; OTCQX: RHHBY) and reMYND today announced that they have entered into an agreement to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients by inhibiting α-synuclein and tau toxicity.